Search

Author/Creator Chen, Helen X

1. Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial. Issue 2 (February 2022)

Authors:
Schoenfeld, Jonathan D; Giobbie-Hurder, Anita; Ranasinghe, Srinika; Kao, Katrina Z; Lako, Ana; Tsuji, Junko; Liu, Yang; Brennick, Ryan C; Gentzler, Ryan D; Lee, Carrie; Hubbard, Joleen; Arnold, Susanne M; Abbruzzese, James L; Jabbour, Salma K; Uboha, Nataliya V; Stephans, Kevin L; Johnson, Jennif...
Journal:
Lancet oncology
Issue:
Volume 23:Issue 2(2022)
Page Start:
279
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with chemotherapy. Issue 3 (14th March 2023)

Authors:
Rizvi, Naiyer; Ademuyiwa, Foluso O; Cao, Z Alexander; Chen, Helen X; Ferris, Robert L; Goldberg, Sarah B; Hellmann, Matthew D; Mehra, Ranee; Rhee, Ina; Park, Jong Chul; Kluger, Harriet; Tawbi, Hussein; Sullivan, Ryan J
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 11:Issue 3(2023)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗